Portfolio of Innovative assets
To heal a world in need.
We are a virology-focused biotech that is on a mission to bring our dynamic portfolio of clinical assets to the patients that need them most.
Focused on healing. Focused on growth.
Just like our namesake Arbutus, a healing plant native to North America, we are leveraging our growing innovative portfolio of assets to focus our efforts on treating and curing conditions with unmet medical need. Today, our virology pipeline has active clinical studies in the area of Hepatitis B virus (HBV).
We are är-‘byü-tuHs. (ARBUTUS)
Here’s what sets us apart.
Focused on combination regimens for maximum impact.
We are committed to harnessing combination drug development to attack different aspects of viruses and to elevate the convenience of finite treatments.
Deep experience in drug development.
Our team includes leaders with the deep scientific and commercial expertise needed to accelerate and strengthen our portfolio’s path to market.
An innovative virology portfolio.
Our RNAi therapeutic, imdusiran has achieved meaningful functional cure rate in patients with cHBV when administered as combination therapy.
HBV
Complementary mechanisms to pursue an HBV cure.
Hepatitis B virus (HBV) therapeutic success requires a multi-faceted approach. Our three-pronged Suppress, Reduce, Boost method harnesses multiple agents with complementary mechanisms of action to maximize impact.
Suppress viral DNA
to stop replication.
Reduce viral antigens
to block HBsAg.
Boost and reawaken
the host’s immune response.
